Retatrutide Research for Fatty Liver Disease
An evidence-based overview of research examining Retatrutide in the context of fatty liver disease. This page synthesizes findings from peer-reviewed literature.
Research Summary
Retatrutide showed extraordinary efficacy in MASLD, with 81-82% reduction in liver fat at 48 weeks. Among treated patients, 89-93% achieved normalization of liver fat (HFF below 5%), compared to 0% with placebo. The glucagon receptor component enables direct hepatic effects.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Fatty Liver Disease
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Retatrutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.